Previous studies have revealed the presence of transthyretin (TTR) on lipop
roteins, To further address this issue, we fractionated plasma Lipoproteins
from 9 normal individuals, 10 familial amyloidotic polyneuropathy (FAP) pa
tients, and 19 hyperlipidemic subjects using gel filtration. In the majorit
y of the subjects, as well as in 9 of the 10 FAP patients and 11 of the 19
patients with hyperlipidemia, TTR was detected by ELISA in the high density
Lipoprotein (HDL) fraction. The presence of TTR in HDL was con firmed by d
irect sequencing and by immunoblotting; using non-reducing conditions, TTR
was found by immunoblotting in a high molecular weight complex, which react
ed also for apolipoprotein A-I (apoA-I), The amount of TTR present in HDL (
HDL-TTR), as quantified by ELISA corresponded to 1-2% of total plasma TTR,
However, no detectable TTR levels were found in HDL fraction from 6 of the
hyperlipidemic subjects. No correlation was found between the lack of TTR i
n HDL and plasma levels of total, LDL-, or HDL-associated cholesterol as we
ll as levels of apoA-I and total plasma TTR, Ligand binding experiments sho
wed that radiolabeled TTR binds to the HDL fraction of individuals with KDL
-TTR but not to the corresponding fractions of individuals devoid of HDL-TT
R, suggesting that HDL composition may interfere with TTR binding. The comp
onent(s) to which TTR binds in the HDL fraction were investigated. Polyclon
al antibody against apoA-I was able to block the interaction of TTR with HD
L, suggesting that the interaction of TTR with the HDL particle occurs via
apoA-I, This hypothesis was further demonstrated by showing the formation o
f a complex of TTR with HDL and apoA-I by crosslinking experiments. Further
more, anti-apoA-I immunoblot under native conditions suggested the existenc
e of differences in HDL particle properties and/or stability between indivi
duals with and without HDL-TTR.